Dr. Sidor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 919-966-4996Fax+1 919-843-5515
Education & Training
- Main Line Health System/Lankenau Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1988
- Sidney Kimmel Medical College at Thomas Jefferson University/Christiana Care Health ServicesResidency, Internal Medicine, 1982 - 1985
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1982
Certifications & Licensure
- NC State Medical License 1993 - 2025
- DE State Medical License 1985 - 2013
- PA State Medical License 1985 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 27 citationsA phase I trial of the aurora kinase inhibitor , ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemiaKaren W.L. Yee, Hsiao-Wei T. Chen, David W. Hedley, Sue Chow, Joseph Brandwein
Investigational New Drugs. 2016-07-12 - 37 citationsENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A. Matulonis, Julie Lee, Brian Lasonde, William P. Tew, Afra Yehwalashet
European Journal of Cancer. 2013-01-01 - 12 citationsPhase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) ...Amye J. Tevaarwerk, George Wilding, Jens C. Eickhoff, Rick Chappell, C. Sidor
Investigational New Drugs. 2012-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: